• Je něco špatně v tomto záznamu ?

Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment

YL. Ma, QQ. Zeng, AY. Chiang, D. Burr, J. Li, H. Dobnig, A. Fahrleitner-Pammer, D. Michalská, F. Marin, I. Pavo, JJ. Stepan,

. 2014 ; 59 (-) : 139-47.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074481

Cortical bone, the dominant component of the human skeleton by volume, plays a key role in protecting bones from fracture. We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN). Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment. At baseline, the frequency of specimens without any endocortical and periosteal tetracycline labeling, and the percentage of quiescent osteons, was higher in the ALN than the TN group. Endocortical and periosteal mineralizing surface (MS/BS%), periosteal bone formation rate (BFR/BS), mineral apposition rate (MAR) and the number of intracortical forming osteons were significantly lower in the ALN-pretreated patients than in the TN group. Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased. Teriparatide treatment resulted in significant increases of MAR in the endocortical, and MS/BS% in the periosteal compartment in the ALN-pretreated group. Most indices of bone formation remained lower in the ALN-pretreated group compared with the TN group at study end. Endocortical wall width was increased in both ALN-pretreated and TN groups. Cortical porosity and cortical thickness were significantly increased in the ALN-pretreated group after teriparatide treatment. Our results suggest that 24months of teriparatide treatment increases cortical bone formation and cortical turnover in patients who were either TN or had previous ALN therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074481
003      
CZ-PrNML
005      
20141007112139.0
007      
ta
008      
141006s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bone.2013.11.011 $2 doi
035    __
$a (PubMed)24269280
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ma, Yanfei L $u Lilly Research Laboratories, Indianapolis, IN, USA. Electronic address: ma_linda@lilly.com.
245    10
$a Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment / $c YL. Ma, QQ. Zeng, AY. Chiang, D. Burr, J. Li, H. Dobnig, A. Fahrleitner-Pammer, D. Michalská, F. Marin, I. Pavo, JJ. Stepan,
520    9_
$a Cortical bone, the dominant component of the human skeleton by volume, plays a key role in protecting bones from fracture. We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN). Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment. At baseline, the frequency of specimens without any endocortical and periosteal tetracycline labeling, and the percentage of quiescent osteons, was higher in the ALN than the TN group. Endocortical and periosteal mineralizing surface (MS/BS%), periosteal bone formation rate (BFR/BS), mineral apposition rate (MAR) and the number of intracortical forming osteons were significantly lower in the ALN-pretreated patients than in the TN group. Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased. Teriparatide treatment resulted in significant increases of MAR in the endocortical, and MS/BS% in the periosteal compartment in the ALN-pretreated group. Most indices of bone formation remained lower in the ALN-pretreated group compared with the TN group at study end. Endocortical wall width was increased in both ALN-pretreated and TN groups. Cortical porosity and cortical thickness were significantly increased in the ALN-pretreated group after teriparatide treatment. Our results suggest that 24months of teriparatide treatment increases cortical bone formation and cortical turnover in patients who were either TN or had previous ALN therapy.
650    _2
$a senioři $7 D000368
650    _2
$a alendronát $x farmakologie $x terapeutické užití $7 D019386
650    _2
$a fyziologická kalcifikace $x účinky léků $7 D002113
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a osteogeneze $x účinky léků $7 D010012
650    _2
$a postmenopauzální osteoporóza $x farmakoterapie $x patofyziologie $7 D015663
650    _2
$a teriparatid $x farmakologie $x terapeutické užití $7 D019379
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zeng, Qing Q $u Lilly Research Laboratories, Indianapolis, IN, USA. Electronic address: zeng_qing_q@lilly.com.
700    1_
$a Chiang, Alan Y $u Lilly Research Laboratories, Indianapolis, IN, USA. Electronic address: chiang_alan_y@lilly.com.
700    1_
$a Burr, David $u Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: dburr@iupui.edu.
700    1_
$a Li, Jiliang $u Department of Biology, Indiana University Purdue University, Indianapolis, IN, USA. Electronic address: jilili@iupui.edu.
700    1_
$a Dobnig, Harald $u Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria. Electronic address: harald.dobnig@hormoninstitut-dobnig.at.
700    1_
$a Fahrleitner-Pammer, Astrid $u Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria. Electronic address: astrid.fahrleitner@medunigraz.at.
700    1_
$a Michalská, Dana $u 3rd Dept. of Internal Medicine, Charles University Faculty of Medicine 1, Prague, Czech Republic. Electronic address: d.michalska@post.cz.
700    1_
$a Marin, Fernando $u Lilly Research Centre, Windlesham, United Kingdom. Electronic address: marin_fernando@lilly.com.
700    1_
$a Pavo, Imre $u Lilly Research Centre, Windlesham, United Kingdom. Electronic address: pavo_imre@lilly.com.
700    1_
$a Stepan, Jan J $u Institute of Rheumatology, and Charles University Faculty of Medicine 1, Prague, Czech Republic. Electronic address: endojs@seznam.cz.
773    0_
$w MED00000833 $t Bone $x 1873-2763 $g Roč. 59, č. - (2014), s. 139-47
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24269280 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20141007112616 $b ABA008
999    __
$a ok $b bmc $g 1042364 $s 873393
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 59 $c - $d 139-47 $i 1873-2763 $m Bone $n Bone $x MED00000833
LZP    __
$a Pubmed-20141006

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace